MCID: CTN007
MIFTS: 61

Cutaneous Leishmaniasis

Categories: Infectious diseases

Aliases & Classifications for Cutaneous Leishmaniasis

MalaCards integrated aliases for Cutaneous Leishmaniasis:

Name: Cutaneous Leishmaniasis 38 12 14
Asian Desert Cutaneous Leishmaniasis 12 69
Diffuse Cutaneous Leishmaniasis 12 69
Leishmaniasis, Cutaneous 42 69
Ethiopian Cutaneous Leishmaniasis 69
Leishmaniasis Diffuse Cutaneous 52
Leishmaniasis Cutaneous 52
Leproid Leishmaniasis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9111
ICD10 33 B55.1
MeSH 42 D016773
NCIt 47 C34768
SNOMED-CT 64 240637006
UMLS 69 C0023283

Summaries for Cutaneous Leishmaniasis

Disease Ontology : 12 A leishmaniasis that involves skin infection caused by Leishmania species, resulting in one or more cutaneous lesions.

MalaCards based summary : Cutaneous Leishmaniasis, also known as asian desert cutaneous leishmaniasis, is related to lagophthalmos and melioidosis. An important gene associated with Cutaneous Leishmaniasis is IFNG (Interferon Gamma), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Miconazole and Miltefosine have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 72 Cutaneous leishmaniasis (also known as oriental sore, tropical sore, chiclero ulcer, chiclero\'s ulcer... more...

Related Diseases for Cutaneous Leishmaniasis

Diseases related to Cutaneous Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
id Related Disease Score Top Affiliating Genes
1 lagophthalmos 30.4 IL10 IL4 TNF
2 melioidosis 29.4 IFNG IL10 TLR2 TLR4 TNF
3 mucocutaneous leishmaniasis 28.6 FOXP3 IFNG IL10 IL4 LMLN PGD
4 leishmaniasis 11.9
5 visceral leishmaniasis 11.3
6 myoclonic astatic epilepsy 10.9 IFNG IL4
7 pure autonomic failure 10.9 IL10 TNF
8 sternal cleft 10.8 IFNG TNF
9 autoimmune polyglandular syndrome type 3 10.8 IFNG TNF
10 multiple familial trichoepithelioma 10.8 IL10 TNF
11 diabetic angiopathy 10.7 IL10 IL4
12 cystadenocarcinoma 10.7 IL10 IL13
13 myotubular myopathy with abnormal genital development 10.7 FCER2 IL4
14 eye accommodation disease 10.7 IFNG IL10 IL4
15 thelaziasis 10.7 IFNG IL10 IL4
16 acute ackee fruit intoxication 10.7 IL10 IL4 TNF
17 type 1 papillary adenoma of the kidney 10.7 IL10 TNF
18 plantar wart 10.7 IFNG IL10 TNF
19 basidiobolomycosis 10.7 IL10 IL4 TNF
20 bulbospinal polio 10.7 IFNG TLR4
21 neutrophil-specific granule deficiency 10.7 IL10 TLR2
22 liver leiomyoma 10.7 IL10 IL4 TNF
23 cyclosporiasis 10.7 IFNG IL10 TNF
24 lymphocytic colitis 10.7 IFNG IL4 TNF
25 hepadnavirus infection 10.7 IFNG IL10 TNF
26 senile reticular retinal degeneration 10.7 IFNG IL10 TNF
27 psychologic dyspareunia 10.7 IFNG IL10 TNF
28 hemophagocytic lymphohistiocytosis 10.7 IFNG IL10 TNF
29 dysphagia 10.7 IFNG IL10 TNF
30 conduct disorder 10.7 IFNG IL10 TNF
31 phlyctenulosis 10.7 IL10 IL4 TNF
32 ethmoid sinus adenocarcinoma 10.6 IL10 SLC11A1 TNF
33 mosaic trisomy 1 10.6 IFNG TNF
34 goat milk allergy 10.6 IFNG IL13 IL4
35 indian tick typhus 10.6 IFNG IL13
36 extrahepatic bile duct adenocarcinoma 10.6 IFNG IL10 TNF
37 papillary squamous carcinoma 10.6 IFNG IL10 IL13
38 reardon wilson cavanagh syndrome 10.6 IFNG IL4 TNF
39 cornea cancer 10.6 IFNG IL10 TNF
40 urethra transitional cell carcinoma 10.6 IL10 SLC11A1 TNF
41 cow milk allergy 10.6 IL10 IL13 IL4
42 noma 10.6 IL10 IL4 TNF
43 primary biliary cirrhosis 10.6 IL10 SLC11A1 TNF
44 dentinogenesis imperfecta 10.6 IFNG IL10 TNF
45 left bundle branch hemiblock 10.6 IFNG IL10 TNF
46 graft-versus-host disease, protection against 10.6 IFNG IL10
47 tarsal tunnel syndrome 10.6 IL10 IL13 TNF
48 vulvar nodular hidradenoma 10.6 IFNG IL10 IL4
49 burn scar 10.6 IFNG IL10 TNF
50 status epilepticus 10.6 IFNG IL4 TNF

Graphical network of the top 20 diseases related to Cutaneous Leishmaniasis:



Diseases related to Cutaneous Leishmaniasis

Symptoms & Phenotypes for Cutaneous Leishmaniasis

MGI Mouse Phenotypes related to Cutaneous Leishmaniasis:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 FCER2 FOXP3 GPI IFNG IL10 IL13
2 digestive/alimentary MP:0005381 10.3 IL5 SLC11A1 TLR2 TLR4 TLR9 TNF
3 cellular MP:0005384 10.28 FCER2 FOXP3 IFNG IL10 IL13 IL4
4 immune system MP:0005387 10.27 FCER2 FOXP3 GPI IFNG IL10 IL13
5 homeostasis/metabolism MP:0005376 10.26 FCER2 FOXP3 GPI IFNG IL10 IL13
6 growth/size/body region MP:0005378 10.25 IFNG FOXP3 GPI IL10 IL13 IL4
7 mortality/aging MP:0010768 10.18 FCER2 FOXP3 GPI IFNG IL10 IL13
8 liver/biliary system MP:0005370 10.06 FOXP3 GPI IFNG IL10 IL4 IL5
9 integument MP:0010771 10.03 FOXP3 IFNG IL10 IL13 IL4 TLR2
10 neoplasm MP:0002006 9.87 IL10 IL5 SLC11A1 TLR2 TLR4 TNF
11 no phenotypic analysis MP:0003012 9.8 FOXP3 GPI IFNG IL10 IL13 IL4
12 reproductive system MP:0005389 9.76 IFNG IL10 IL13 IL4 IL5 TLR4
13 respiratory system MP:0005388 9.65 FOXP3 GPI IFNG IL10 IL13 IL4
14 skeleton MP:0005390 9.28 IFNG IL10 IL13 IL4 MPI PGD

Drugs & Therapeutics for Cutaneous Leishmaniasis

Drugs for Cutaneous Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Miltefosine Approved Phase 4,Phase 3,Phase 2 58066-85-6 3600
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
4 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 meglumine antimoniate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anthelmintics Phase 4,Phase 2,Phase 1
10 Antimony Sodium Gluconate Phase 4,Phase 2,Phase 1
11 Anesthetics Phase 4
12
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
13
Paromomycin Approved, Investigational Phase 3,Phase 2,Early Phase 1 1263-89-4, 7542-37-2 165580
14
Imiquimod Approved, Investigational Phase 3,Phase 2 99011-02-6 57469
15
Aluminum sulfate Approved Phase 2, Phase 3, Phase 1 10043-01-3
16
Nitric Oxide Approved Phase 3 10102-43-9 145068
17
Pentamidine Approved Phase 2, Phase 3 100-33-4 4735
18
Fluconazole Approved Phase 3 86386-73-4 3365
19
Azithromycin Approved Phase 2, Phase 3 83905-01-5 55185 53477736 447043
20 Tocopherol Approved, Nutraceutical Phase 3
21
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
22 Antioxidants Phase 2, Phase 3
23 Phosphodiesterase Inhibitors Phase 2, Phase 3
24 Platelet Aggregation Inhibitors Phase 2, Phase 3
25 Protective Agents Phase 2, Phase 3
26 Radiation-Protective Agents Phase 2, Phase 3
27 Vasodilator Agents Phase 2, Phase 3
28 Adjuvants, Immunologic Phase 2, Phase 3, Phase 1
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antibiotics, Antitubercular Phase 3,Phase 2
31 Gentamicins Phase 3,Phase 2
32 Interferon Inducers Phase 3,Phase 2
33 interferons Phase 3,Phase 2
34 Vaccines Phase 2, Phase 3, Phase 1
35 Anti-Asthmatic Agents Phase 3
36 Autonomic Agents Phase 3
37 Bronchodilator Agents Phase 3
38 Endothelium-Dependent Relaxing Factors Phase 3
39 Neurotransmitter Agents Phase 3,Phase 2
40 Peripheral Nervous System Agents Phase 3
41 Respiratory System Agents Phase 3
42 Tocopherols Phase 3
43 Tocotrienols Phase 3
44 Vitamins Phase 3
45 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
46 Cytochrome P-450 Enzyme Inhibitors Phase 3
47 Hormone Antagonists Phase 3
48 Hormones Phase 3
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
50 Steroid Synthesis Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 83)

id Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
2 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4 Meglumine antimoniate
3 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4 Miltefosine
4 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
5 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
6 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
7 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
8 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
9 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
10 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3 Imiquimod
11 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
12 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
13 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
14 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
15 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
16 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
17 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
18 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
19 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Active, not recruiting NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
20 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
21 Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan Not yet recruiting NCT03208543 Phase 3
22 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Not yet recruiting NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
23 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
24 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
25 Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
26 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
27 Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
28 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World Completed NCT00703924 Phase 2 WR 279,396;Placebo
29 Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil) Completed NCT00600548 Phase 2 Miltefosine.;Meglumine antimoniate.;Miltefosine.;Meglumine antimoniate.
30 WR 279,396 for the Treatment of Cutaneous Leishmaniasis Completed NCT01988909 Phase 2 WR 279,396
31 Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia Completed NCT01845727 Phase 1, Phase 2 Topical Amphotericin B at 3%
32 Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis Completed NCT00973128 Phase 2 GMCSF plus Antimony reduced dose;Meglumine antimoniate
33 Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis Completed NCT02919605 Phase 2 Single dose of Pentacarinat®;Two doses of Pentacarinat®;Three doses of Pentacarinat®
34 Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Completed NCT00233545 Phase 2 miltefosine;antimony
35 Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis Completed NCT01380314 Phase 2 Miltefosine + Imiquimod;Miltefosine 150 mg x day + Placebo
36 Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis Completed NCT00884377 Phase 2 Sodium stibogluconate (Pentostam)
37 A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis Completed NCT01011309 Phase 2 Sodium stibogluconate
38 A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis Completed NCT01536795 Phase 2 WR279 396 with Tegaderm Dressing;WR 279, 396 with Gauze and Tape Dressing
39 Intralesional Antimony for Bolivian Cutaneous Leishmaniasis Completed NCT01300975 Phase 2 pentavalent antimony;placebo cream
40 Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Completed NCT03294161 Phase 2 Immucillin DI4G;Meglumine antimoniate
41 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01083576 Phase 2 WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream);Paromomycin Alone Cream (15% paromomycin topical cream)
42 Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Completed NCT00004755 Phase 2 allopurinol;glucantime
43 Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) Completed NCT01032382 Phase 2 WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream);Paromomycin Alone Cream (15% paromomycin topical cream)
44 Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients Completed NCT00996463 Phase 2 Sodium Stibogluconate;DAC N-055
45 Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396 Completed NCT00657917 Phase 2 Paromomycin +Gentamicin topical cream
46 Miltefosine to Treat Mucocutaneous Leishmaniasis Completed NCT01050907 Phase 2 miltefosine
47 Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite Completed NCT00121862 Phase 2
48 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen Completed NCT00633009 Phase 2
49 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
50 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2 Sodium Stibogluconate (SSG)

Search NIH Clinical Center for Cutaneous Leishmaniasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leishmaniasis, cutaneous

Genetic Tests for Cutaneous Leishmaniasis

Anatomical Context for Cutaneous Leishmaniasis

MalaCards organs/tissues related to Cutaneous Leishmaniasis:

39
Skin, Testes, T Cells, Monocytes, Neutrophil, Breast, Placenta

Publications for Cutaneous Leishmaniasis

Articles related to Cutaneous Leishmaniasis:

(show top 50) (show all 761)
id Title Authors Year
1
Spatial distribution, Leishmania species and clinical traits of Cutaneous Leishmaniasis cases in the Colombian army. ( 28850603 )
2017
2
Screening of TNFI+, IL-10 and TLR4 single nucleotide polymorphisms in individuals with asymptomatic and chronic cutaneous leishmaniasis in Colombia: a pilot study. ( 28241747 )
2017
3
The new situation of cutaneous leishmaniasis after Syrian civil war in Gaziantep city, Southeastern region of Turkey. ( 27983970 )
2017
4
Cutaneous leishmaniasis in a severely immunocompromised HIV patient in Kumbo, Northwest region of Cameroon: case report. ( 28841834 )
2017
5
Aspects on the Ecology of Phlebotomine Sand Flies (Diptera: Psychodidae) From GuaraA-, State of Tocantins, Brazil, Endemic Area for American Cutaneous Leishmaniasis. ( 28082651 )
2017
6
Leech therapy in treatment of cutaneous leishmaniasis: a case report. ( 28844218 )
2017
7
Effect of secondary infection on epithelialisation and total healing of cutaneous leishmaniasis lesions. ( 28902290 )
2017
8
A Case of Cutaneous Leishmaniasis guyanensis Mimicking Otitis Externa. ( 28811000 )
2017
9
Spatiotemporal and molecular epidemiology of cutaneous leishmaniasis in Libya. ( 28880944 )
2017
10
First report on molecular characterization of Leishmania species from cutaneous leishmaniasis patients in southern Khyber Pakhtunkhwa province of Pakistan. ( 28870350 )
2017
11
Reprint of "Spatial modeling of Cutaneous Leishmaniasis in Iran from 1983 to 2013". ( 27914666 )
2017
12
The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. ( 28043177 )
2017
13
First description of Leishmania (Viannia) infection in Evandromyia saulensis, Pressatia sp. and Trichophoromyia auraensis (Psychodidae: Phlebotominae) in a transmission area of cutaneous leishmaniasis in Acre state, Amazon Basin, Brazil. ( 28076470 )
2017
14
Effects of Bone Marrow Mesenchymal Stromal Cell Therapy in Experimental Cutaneous Leishmaniasis in BALB/c Mice Induced by Leishmania amazonensis. ( 28848541 )
2017
15
Phlebotomines in an area endemic for American cutaneous leishmaniasis in northeastern coast of Brazil. ( 28902258 )
2017
16
Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. ( 28926630 )
2017
17
An Anti-Inflammatory Role for NLRP10 in Murine Cutaneous Leishmaniasis. ( 28931602 )
2017
18
Modeling zoonotic cutaneous leishmaniasis incidence in central Tunisia from 2009-2015: Forecasting models using climate variables as predictors. ( 28841642 )
2017
19
Detection and identification of cutaneous leishmaniasis isolates by culture, Polymerase chain reaction and sequence analyses in Syrian and Central Anatolia patients. ( 28889158 )
2017
20
In Vitro Immunomodulatory Activity of a Transition-State Analog Inhibitor of Human Purine Nucleoside Phosphorylase in Cutaneous Leishmaniasis. ( 28929123 )
2017
21
In Vitro and In Vivo Evaluation of Essential Oil from Artemisia absinthium L. Formulated in Nanocochleates against Cutaneous Leishmaniasis. ( 28930253 )
2017
22
Histopathologic features of cutaneous leishmaniasis and use of CD1a staining for amastigotes in Old World and New World leishmaniasis. ( 28892183 )
2017
23
Leishmania tropica: Combined debulking and imiquimod for the treatment of nonresponsive cutaneous leishmaniasis. ( 27986151 )
2017
24
Considerations of potential vectors and animal reservoirs in an emerging cutaneous leishmaniasis area in SALo Domingos ranch, ParanA! State in Southearn Brazil. ( 28876416 )
2017
25
Cutaneous leishmaniasis in Algeria: quadrennial assessment (2008-2011). ( 28947409 )
2017
26
SLC11A1 polymorphisms and host susceptibility to cutaneous leishmaniasis in Pakistan. ( 28061874 )
2017
27
A case report of co-infection of Melioidosis and cutaneous Leishmaniasis. ( 28764662 )
2017
28
Spatial distribution of cutaneous leishmaniasis in the state of ParanA!, Brazil. ( 28938013 )
2017
29
Assessing the insecticide susceptibility status of field population of Phlebotomus papatasi (Diptera: Psychodidae) in a hyperendemic area of zoonotic cutaneous leishmaniasis in Esfahan Province, Central Iran. ( 28870534 )
2017
30
Sporothrix schenckii Sensu Lato identification in fragments of skin lesion cultured in NNN medium for differential diagnosis of cutaneous leishmaniasis. ( 27914747 )
2017
31
Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins. ( 27642328 )
2016
32
Intralesional Versus Oral Chloroquine in Cutaneous Leishmaniasis: Comparison of Outcome, Duration of Treatment and Total Dose of Drug. ( 27097693 )
2016
33
Cutaneous Leishmaniasis: The Truth about the 'Flesh-Eating Disease' in Syria. ( 27105932 )
2016
34
Antileishmanial activity of ezetimibe: inhibition of sterol biosynthesis, in vitro synergy with azoles and efficacious in experimental cutaneous leishmaniasis. ( 27600041 )
2016
35
Exploratory, Phase II Controlled Trial of Shiunko Ointment Local Application Twice a Day for 4 Weeks in Ethiopian Patients with Localized Cutaneous Leishmaniasis. ( 27195014 )
2016
36
Characterization of Neutrophil Function in Human Cutaneous Leishmaniasis Caused by Leishmania braziliensis. ( 27167379 )
2016
37
DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis. ( 27922065 )
2016
38
Cutaneous Leishmaniasis in Khyber Pakhtunkhwa Province of Pakistan: Clinical Diversity and Species-Level Diagnosis. ( 27601518 )
2016
39
Identification of Leishmania Species Isolated from Human Cutaneous Leishmaniasis in Mehran, Western Iran Using Nested PCR. ( 27095970 )
2016
40
Aspects on the Ecology of Phlebotomine Sand Flies (Diptera: Psychodidae) From GuaraA-, State of Tocantins, Brazil, Endemic Area for American Cutaneous Leishmaniasis. ( 27590233 )
2016
41
A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations. ( 27109311 )
2016
42
Topical Simvastatin as Host-Directed Therapy against Severity of Cutaneous Leishmaniasis in Mice. ( 27632901 )
2016
43
NRAMP1 gene polymorphisms and cutaneous leishmaniasis: An evaluation on host susceptibility and treatment outcome. ( 27681549 )
2016
44
Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole. ( 27549634 )
2016
45
Amiodarone triggers induction of apoptosis in cutaneous leishmaniasis agents. ( 27553974 )
2016
46
Clinicoepidemiologic pattern of cutaneous leishmaniasis and molecular characterization of its causative agent in Hajjah governorate, northwest of Yemen. ( 27515810 )
2016
47
Molecular Epidemiological Survey of Cutaneous Leishmaniasis in Two Highly Endemic Metropolises of Iran, Application of FTA Cards for DNA Extraction From Giemsa-Stained Slides. ( 27127596 )
2016
48
The sesquiterpene (-)-I+-bisabolol is active against the causative agents of Old World cutaneous leishmaniasis through the induction of mitochondrial-dependent apoptosis. ( 27539477 )
2016
49
Panniculitis is a common unrecognized histopathological feature of cutaneous leishmaniasis. ( 26960628 )
2016
50
Spatial Analyses of the Relation between Rodent's Active Burrows and Incidence of Zoonotic Cutaneous Leishmaniasis in Golestan Province, Northeastern of Iran. ( 28032109 )
2016

Variations for Cutaneous Leishmaniasis

Expression for Cutaneous Leishmaniasis

LifeMap Discovery
Genes differentially expressed in tissues of Cutaneous Leishmaniasis patients vs. healthy controls: 35 (show top 50) (show all 174)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL9 chemokine (C-X-C motif) ligand 9 Skin + 6.42 0.000
2 CXCL10 chemokine (C-X-C motif) ligand 10 Skin + 6.16 0.000
3 IDO1 indoleamine 2,3-dioxygenase 1 Skin + 5.97 0.000
4 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) Skin + 5.88 0.000
5 GBP5 guanylate binding protein 5 Skin + 5.82 0.000
6 PIP prolactin-induced protein Skin - 5.80 0.000
7 GNLY granulysin Skin + 5.77 0.000
8 MMP1 matrix metallopeptidase 1 Skin + 5.47 0.000
9 DCD dermcidin Skin - 5.36 0.000
10 GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) Skin + 5.30 0.000
11 SCGB1D2 secretoglobin, family 1D, member 2 Skin - 5.14 0.000
12 CCL8 chemokine (C-C motif) ligand 8 Skin + 5.01 0.000
13 NKG7 natural killer cell granule protein 7 Skin + 4.99 0.000
14 GZMK granzyme K (granzyme 3; tryptase II) Skin + 4.89 0.000
15 SCGB2A2 secretoglobin, family 2A, member 2 Skin - 4.87 0.000
16 IGLL1 immunoglobulin lambda-like polypeptide 1 Skin + 4.82 0.000
17 CCL5 chemokine (C-C motif) ligand 5 Skin + 4.78 0.000
18 MMP3 matrix metallopeptidase 3 Skin + 4.69 0.000
19 CCL3L3 chemokine (C-C motif) ligand 3-like 3 Skin + 4.67 0.000
20 UBD ubiquitin D Skin + 4.67 0.000
21 ADAMDEC1 ADAM-like, decysin 1 Skin + 4.65 0.000
22 EPSTI1 epithelial stromal interaction 1 (breast) Skin + 4.53 0.000
23 JCHAIN joining chain of multimeric IgA and IgM Skin + 4.53 0.000
24 C5orf46 chromosome 5 open reading frame 46 Skin - 4.53 0.000
25 C1QB complement component 1, q subcomponent, B chain Skin + 4.51 0.000
26 GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) Skin + 4.48 0.000
27 GBP1 guanylate binding protein 1, interferon-inducible Skin + 4.45 0.000
28 CCL4L1 chemokine (C-C motif) ligand 4-like 1 Skin + 4.44 0.000
29 MED27 mediator complex subunit 27 Skin - 4.31 0.000
30 FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide Skin + 4.29 0.000
31 KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 Skin + 4.27 0.000
32 SERPINA12 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12 Skin - 4.25 0.000
33 GBP4 guanylate binding protein 4 Skin + 4.23 0.000
34 CD8A CD8a molecule Skin + 4.23 0.000
35 TDO2 tryptophan 2,3-dioxygenase Skin + 4.19 0.000
36 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) Skin + 4.17 0.000
37 CXCL8 chemokine (C-X-C motif) ligand 8 Skin + 4.13 0.000
38 KRT27 keratin 27, type I Skin - 4.13 0.000
39 DAPL1 death associated protein-like 1 Skin - 4.10 0.000
40 LYZ lysozyme Skin + 4.10 0.000
41 THRSP thyroid hormone responsive Skin - 4.06 0.000
42 CHP2 calcineurin-like EF-hand protein 2 Skin - 4.03 0.000
43 PRF1 perforin 1 (pore forming protein) Skin + 4.03 0.000
44 LAG3 lymphocyte-activation gene 3 Skin + 3.99 0.000
45 CYBB cytochrome b-245, beta polypeptide Skin + 3.98 0.000
46 WARS tryptophanyl-tRNA synthetase Skin + 3.98 0.000
47 CD3D CD3d molecule, delta (CD3-TCR complex) Skin + 3.97 0.000
48 IL18BP interleukin 18 binding protein Skin + 3.96 0.000
49 SNX10 sorting nexin 10 Skin + 3.96 0.000
50 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 Skin + 3.95 0.000
Search GEO for disease gene expression data for Cutaneous Leishmaniasis.

Pathways for Cutaneous Leishmaniasis

Pathways related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 FCER2 GPI IFNG IL10 IL13 IL4
2
Show member pathways
13.65 FCER2 IFNG IL10 IL13 IL4 IL5
3
Show member pathways
13.44 IL10 IL13 IL4 IL5 TLR2 TLR4
4
Show member pathways
13.36 FCER2 IFNG IL10 IL13 IL4 IL5
5
Show member pathways
13.23 FCER2 IFNG IL4 TLR2 TLR4 TLR9
6
Show member pathways
12.93 IFNG IL10 TLR2 TLR4 TLR9 TNF
7
Show member pathways
12.91 FOXP3 IFNG IL10 IL13 IL4 IL5
8
Show member pathways
12.86 IFNG IL13 IL4 TLR2 TLR4 TLR9
9 12.55 FOXP3 IFNG IL10 IL4 TLR2 TLR9
10
Show member pathways
12.49 IFNG IL10 IL4 IL5 TNF
11
Show member pathways
12.39 IFNG IL13 IL4 IL5 TLR2 TNF
12
Show member pathways
12.35 FOXP3 IFNG IL10 IL13 IL4 IL5
13
Show member pathways
12.31 IFNG IL10 IL4 TLR2 TLR4 TNF
14
Show member pathways
12.28 IFNG IL10 IL13 IL4 IL5
15 12.27 IFNG IL10 TLR2 TLR4 TLR9 TNF
16 12.25 IFNG TLR2 TLR4 TLR9 TNF
17
Show member pathways
12.22 IFNG IL4 TLR2 TLR4 TLR9 TNF
18
Show member pathways
12.18 IFNG IL10 IL13 IL4 IL5 TNF
19
Show member pathways
12.11 IL13 IL5 TLR2 TLR4 TLR9
20 12.08 IFNG IL10 IL4 IL5 TNF
21 12.07 IFNG IL4 TLR4 TNF
22 12.06 FCER2 IL10 IL13 IL4 TNF
23 11.97 FCER2 IL4 IL5 TNF
24
Show member pathways
11.97 IFNG IL4 TLR2 TLR4 TLR9
25 11.96 IFNG IL10 TLR2 TLR4 TNF
26
Show member pathways
11.96 IFNG IL10 TLR2 TLR4 TLR9 TNF
27 11.93 IFNG TLR2 TLR4 TNF
28 11.9 FCER2 TLR2 TLR4 TLR9
29 11.88 IFNG IL13 IL4 IL5
30 11.84 IFNG IL10 TLR9 TNF
31
Show member pathways
11.83 FOXP3 IFNG IL4 IL5 TNF
32 11.78 IFNG IL10 IL13 IL4 IL5 TNF
33 11.76 IL10 TLR4 TNF
34 11.76 FCER2 IL10 IL4 IL5
35 11.75 IL13 IL4 IL5 TNF
36 11.62 TLR2 TLR4 TNF
37 11.62 IFNG TLR2 TLR4 TNF
38 11.57 FCER2 IL10 IL13 IL4 TNF
39
Show member pathways
11.5 FOXP3 IFNG IL10 TNF
40 11.49 IFNG IL10 TLR2 TLR4 TLR9 TNF
41 11.44 IFNG IL10 TLR9 TNF
42 11.42 IL10 TLR4 TNF
43 11.41 FOXP3 IFNG IL10 IL13 IL4 IL5
44 11.39 IFNG IL4 IL5
45 11.34 IFNG IL13 IL4 IL5 TNF
46 11.29 IL10 IL13 IL4 IL5 TNF
47 11.18 IFNG IL10 IL13 IL4 IL5
48 11.07 FOXP3 IL10 IL4 IL5 TLR2 TLR4
49 10.99 IL13 IL4 IL5
50 10.91 IFNG IL10 IL13 IL4 IL5 TNF

GO Terms for Cutaneous Leishmaniasis

Cellular components related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 GPI IFNG IL10 IL13 IL4 IL5
2 extracellular region GO:0005576 9.61 FCER2 GPI IFNG IL10 IL13 IL4
3 external side of plasma membrane GO:0009897 9.1 FCER2 IFNG IL13 IL4 TLR4 TNF

Biological processes related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TLR2 TLR4 TLR9 TNF
2 cellular response to lipopolysaccharide GO:0071222 9.97 IFNG IL10 TLR4 TNF
3 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.95 IL10 IL4 IL5 TNF
4 response to virus GO:0009615 9.93 FOXP3 IFNG TNF
5 defense response to Gram-negative bacterium GO:0050829 9.92 SLC11A1 TLR4 TLR9
6 positive regulation of JNK cascade GO:0046330 9.91 TLR4 TLR9 TNF
7 positive regulation of inflammatory response GO:0050729 9.91 TLR2 TLR4 TLR9
8 humoral immune response GO:0006959 9.9 GPI IFNG TNF
9 toll-like receptor signaling pathway GO:0002224 9.89 TLR2 TLR4 TLR9
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.89 IFNG TLR4 TNF
11 positive regulation of interferon-gamma production GO:0032729 9.89 SLC11A1 TLR4 TNF
12 positive regulation of tumor necrosis factor production GO:0032760 9.88 IFNG TLR2 TLR4 TLR9
13 negative regulation of tumor necrosis factor production GO:0032720 9.86 FOXP3 IL10 TLR4
14 positive regulation of interleukin-6 production GO:0032755 9.86 TLR2 TLR4 TLR9 TNF
15 inflammatory response GO:0006954 9.86 IL10 IL13 IL5 SLC11A1 TLR2 TLR4
16 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.84 TLR2 TLR4 TLR9
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TLR2 TLR4 TNF
18 negative regulation of endothelial cell apoptotic process GO:2000352 9.83 IL10 IL13 IL4
19 positive regulation of interleukin-8 production GO:0032757 9.83 TLR2 TLR4 TLR9 TNF
20 positive regulation of interferon-beta production GO:0032728 9.82 TLR2 TLR4 TLR9
21 negative regulation of interferon-gamma production GO:0032689 9.81 FOXP3 IL10 TLR4
22 negative regulation of growth of symbiont in host GO:0044130 9.81 IFNG IL10 TNF
23 positive regulation of interleukin-12 production GO:0032735 9.8 IFNG TLR2 TLR4 TLR9
24 microglial cell activation GO:0001774 9.79 IL13 IL4 TLR2
25 response to molecule of bacterial origin GO:0002237 9.79 IL10 TLR2 TLR9
26 I-kappaB phosphorylation GO:0007252 9.78 TLR2 TLR4 TLR9
27 positive regulation of interleukin-10 production GO:0032733 9.78 IL4 TLR2 TLR4 TLR9
28 regulation of cytokine secretion GO:0050707 9.77 TLR2 TLR4 TLR9
29 negative regulation of interleukin-17 production GO:0032700 9.77 FOXP3 IFNG TLR4
30 positive regulation of chemokine biosynthetic process GO:0045080 9.76 IFNG IL4 TNF
31 defense response to protozoan GO:0042832 9.76 IFNG IL10 IL4 SLC11A1
32 negative regulation of nitric oxide biosynthetic process GO:0045019 9.75 IL10 IL4
33 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.75 IFNG TNF
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 IL10 TNF
35 positive regulation of immunoglobulin secretion GO:0051024 9.75 GPI IL5
36 positive regulation of podosome assembly GO:0071803 9.74 IL5 TNF
37 positive regulation of mast cell degranulation GO:0043306 9.74 IL13 IL4
38 cellular response to lipoteichoic acid GO:0071223 9.74 TLR2 TLR4
39 positive regulation of isotype switching to IgG isotypes GO:0048304 9.74 IFNG IL4
40 macrophage activation GO:0042116 9.74 SLC11A1 TLR4
41 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.73 TLR4 TNF
42 endothelial cell apoptotic process GO:0072577 9.73 IL10 TNF
43 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 IFNG IL4
44 positive regulation of interferon-beta biosynthetic process GO:0045359 9.73 TLR4 TLR9
45 positive regulation of NF-kappaB import into nucleus GO:0042346 9.73 TLR2 TLR4 TLR9 TNF
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.72 IL10 TNF
47 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.72 IFNG TLR4
48 type 2 immune response GO:0042092 9.72 IL10 IL4
49 negative regulation of interleukin-8 production GO:0032717 9.72 IL10 TLR9
50 negative regulation of T-helper 17 cell differentiation GO:2000320 9.71 FOXP3 IL4

Molecular functions related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 GPI IL10 IL4 IL5
2 cytokine activity GO:0005125 9.17 GPI IFNG IL10 IL13 IL4 IL5
3 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4

Sources for Cutaneous Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....